Ardelyx responds to reports of Zydus Lifesciences acquisition talks, as Zydus explores funding via QIP. Ardelyx has IBSRELA and XYPHOZAH approved in the US, with a market cap of 1.6 billion dollars.
Ardelyx responds to reports of Zydus Lifesciences acquisition talks, as Zydus explores funding via QIP. Ardelyx has IBSRELA and XYPHOZAH approved in the US, with a market cap of 1.6 billion dollars.